PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose

• Published in: PloS one Vol. 7; no. 3; p. e34019
• Main Authors: Arora, Geetanjali, Shukla, Jaya, Ghosh, Sourabh, Maulik, Subir Kumar, Malhotra, Arun, Bandopadhyaya, Gurupad
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.03.2012; Public Library of Science (PLoS)
• Subjects: Acids; Animals; Background radiation; Biology; Breast cancer; Cancer therapies; Chemistry; Coating; Dosimetry; Drug delivery systems; Drug dosages; Drugs; Health aspects; Kidney; Kidneys; Kinetics; Lactic Acid - pharmacology; Liver; Lutetium; Materials Science; Medical research; Medicine; Nanoparticles; Nanoparticles - administration & dosage; Neuroendocrine tumors; Neuroendocrine Tumors - radiotherapy; Nuclear medicine; Octreotide - analogs & derivatives; Octreotide - pharmacology; Organometallic Compounds - pharmacology; Overexpression; Peptides; Polyethylene glycol; Polyglycolic Acid - pharmacology; Polylactide-co-glycolide; Polyols; Radiation; Radiation Dosage; Radiation effects; Radiation therapy; Radioisotopes; Rats; Rats, Wistar; Receptors; Receptors, Somatostatin; Retention; Somatostatin; Somatostatin receptors; Studies; Therapy; Tumors; India

Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation expos...